Form 4 for VRDN Viridian Therapeutics, Inc.\DE
Accepted 2023-06-20 00:00:00 ET · period of report 2023-06-15 · accession 0000899243-23-015998 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-06-20 | 2023-06-15+ | VRDN | Meisner Lara | CLO | S - Sale+OE | $28.02 | -2,296 | 30.0K | -7% | -$64.3K |
| DM | 2023-06-20 | 2023-06-15+ | VRDN | Meisner Lara | CLO | M - OptEx | $23.03 | +2,296 | 30.0K | +8% | +$52.9K |
| DM | 2023-06-20 | 2023-06-15+ | VRDN | Meisner Lara | CLO | M - OptEx | $0.00 | -2,297 | 37.5K | -6% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-15 | S | D | 2,269 | $28.02 | 29,971 | D | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 7, 2023 (the "Plan") in multiple trades at prices ranging from $28.00 to $28.09. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 2 | Common | Common Stock | 2023-06-16 | S | D | 27 | $28.35 | 29,971 | D | — | — | |
| 3 | Common | Common Stock | 2023-06-15 | M | A | 2,269 | $23.03 | 32,240 | D | — | — | |
| 4 | Common | Common Stock | 2023-06-16 | M | A | 27 | $23.03 | 29,998 | D | — | — | |
| 5 | Derivative | Stock Option (Right to Buy) | 2023-06-15 | M | D | 2,269 | $0.00 | 37,481 | D | $23.03 · — to 2031-01-18 | 2,269 Common Stock | (F3) The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. |
| 6 | Derivative | Stock Option (Right to Buy) | 2023-06-16 | M | D | 28 | $0.00 | 37,453 | D | $23.03 · — to 2031-01-18 | 28 Common Stock | (F3) The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. |